PLSE
Pulse Biosciences, Inc.
$25.89
+0.33
(+1.29%)
Mkt Cap
1.79B
Volume
206,453
52W Range
12.56-27.98
Sector
Healthcare
Beta
1.63
EPS (TTM)
-1.09
P/E Ratio
-12.71
Revenue (TTM)
751,000
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 350,000 | 0 | 0 | 700,000 | 1.42M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.78M) | (53.59M) | (42.21M) | (58.51M) | (63.66M) | (49.74M) | (45.99M) | (37.55M) | (25.57M) | (9.52M) | (2.81M) | (474,857) |
| EPS | -1.08 | -0.92 | -0.88 | -1.72 | -2.28 | -2.14 | -2.22 | -2.20 | -1.73 | -0.86 | -0.37 | -0.19 |
| Free Cash Flow | (54.44M) | (36.47M) | (33.16M) | (47.41M) | (54.53M) | (35.81M) | (34.79M) | (24.17M) | (13.64M) | (8.12M) | N/A | N/A |
| FCF / Share | -0.81 | -0.62 | -0.69 | -1.40 | -1.95 | -1.54 | -1.68 | -1.42 | -0.92 | -0.74 | N/A | N/A |
| Operating CF | (54.12M) | (36.34M) | (33.04M) | (47.01M) | (54.10M) | (35.37M) | (34.19M) | (23.90M) | (11.09M) | (8.05M) | N/A | N/A |
| Total Assets | 96.11M | 132.46M | 59.15M | 77.88M | 54.25M | 41.29M | 41.91M | 70.64M | 49.82M | 26.31M | N/A | N/A |
| Total Debt | 7.53M | 8.90M | 9.14M | 75.96M | 11.25M | 11.36M | 6.72M | 0 | 0 | 0 | N/A | N/A |
| Cash & Equiv | 80.73M | 118.04M | 44.37M | 61.14M | 28.61M | 12.46M | 6.90M | 51.10M | 3.39M | 2.09M | N/A | N/A |
| Book Value | 80.66M | 114.86M | 44.36M | (2.25M) | 35.69M | 22.89M | 30.74M | 66.33M | 45.99M | 25.30M | N/A | N/A |
| Return on Equity | -0.90 | -0.47 | -0.95 | N/A | -1.78 | -2.17 | -1.50 | -0.57 | -0.56 | -0.38 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 401,000 | 264,000 | 86,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (18.58M) | (17.43M) | (19.39M) | (19.17M) | (16.80M) | (19.39M) | (12.68M) | (11.38M) | (10.14M) | (11.93M) | (10.57M) | (9.91M) |
| EPS | -0.26 | -0.26 | -0.29 | -0.28 | -0.25 | -0.33 | -0.21 | -0.20 | -0.18 | -0.22 | -0.19 | -0.22 |
| Free Cash Flow | (14.63M) | (14.86M) | (13.10M) | (12.91M) | (13.57M) | (9.20M) | (9.06M) | (8.42M) | (9.79M) | (6.82M) | (10.51M) | (9.22M) |
| FCF / Share | -0.22 | -0.22 | -0.19 | -0.19 | -0.20 | -0.16 | -0.15 | -0.15 | -0.18 | -0.12 | -0.19 | -0.21 |
| Operating CF | (14.60M) | (14.76M) | (13.04M) | (12.81M) | (13.52M) | (9.14M) | (9.02M) | (8.39M) | (9.78M) | (6.78M) | (10.49M) | (9.20M) |
| Total Assets | 81.62M | 96.11M | 108.77M | 120.25M | 133.38M | 132.46M | 93.05M | 40.43M | 49.16M | 59.15M | 65.94M | 74.76M |
| Total Debt | 7.16M | 7.53M | 7.89M | 8.24M | 8.58M | 8.90M | 8.37M | 8.64M | 8.90M | 9.14M | 9.38M | 9.62M |
| Cash & Equiv | 68.32M | 80.73M | 95.21M | 106.35M | 119.28M | 118.04M | 79.03M | 26.20M | 34.88M | 44.37M | 50.39M | 58.75M |
| Book Value | 66.30M | 80.66M | 92.69M | 104.49M | 118.45M | 114.86M | 79.13M | 26.97M | 36.29M | 44.36M | 52.15M | 60.50M |
| Return on Equity | -0.28 | -0.22 | -0.21 | -0.18 | -0.14 | -0.17 | -0.16 | -0.42 | -0.28 | -0.27 | -0.20 | -0.16 |
PLSE News
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
Pulse Biosciences Q1 Earnings Call Highlights
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Pulse Biosciences, Inc. (PLSE) Shareholder/Analyst Call Transcript